Elsevier, ASIP to publish The American Journal of Pathology

NewsGuard 100/100 Score

Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce that as of January 2011 Elsevier will publish The American Journal of Pathology (AJP) in partnership with the American Society for Investigative Pathology (ASIP).

The American Journal of Pathology is the official publication of the American Society for Investigative Pathology. Under the guidance of Editor-in-Chief Michael P. Lisanti, MD, PhD, Thomas Jefferson University, Philadelphia, PA, AJP is a monthly, peer-reviewed, scholarly publication that reports cutting-edge science which advances basic and translational knowledge of disease pathogenesis, classification, and diagnosis, as well as basic biological mechanisms relating to disease. It is the leading global forum for reporting quality original research on cellular and molecular mechanisms of disease. Articles include studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

"Elsevier is truly honored to partner with the American Society for Investigative Pathology to publish The American Journal of Pathology. This premier journal represents the highest-quality research, covering a broad range of topics and specialties. As such, the fit with our current publishing program is excellent," states Andrew Berin, Publishing Director, Elsevier.

Dr. Mark E. Sobel, ASIP's Executive Officer, states, "ASIP looks forward to its partnership with Elsevier, which will serve to further the Society's mission of disseminating high-quality research and information about the cellular and molecular mechanisms of disease. We are confident that Elsevier's expertise, innovative technology, and global presence will serve to expand the reach and impact of our flagship journal, The American Journal of Pathology."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cytokine interferon-gamma can be a disease-modifying therapeutic target in multiple system atrophy